Extracorporeal membrane oxygenation (ECMO) has always been a therapy defined by its ability to buy time; time for a heart to recover, for lungs to heal, or for a transplant to become possible. But a recently published case report from Northwestern Medicine introduces a new way of buying time — one that has only been attempted a handful of times in any form, and never quite like this. The case challenges not just what ECMO can support, but what is even survivable with the right circuit design behind it.
The Case at a Glance
A 33-year-old previously healthy man presented with influenza B-associated ARDS, a condition that, when complicated by drug-resistant infection and septic shock, carries mortality exceeding 80%. Over six weeks, he developed necrotizing pneumonia caused by carbapenem-resistant Pseudomonas aeruginosa, an organism that proved impossible to eradicate despite aggressive antimicrobial therapy, chest drainage, and full venoarterial ECMO support. He was experiencing recurrent episodes of pulseless electrical activity (PEA) driven by refractory septic shock, and every available treatment option had been exhausted.
The clinical picture left the Northwestern team with a stark conclusion: as long as the infected lungs remained in the chest, the infection could not be controlled and the patient would not survive. The only remaining path forward was to remove both lungs entirely, eliminating the source of infection and creating the conditions that might make transplantation possible.
Why Bilateral Pneumonectomy Is Almost Never Done
Lung transplantation for ARDS is itself uncommon, but it does occur, primarily in cases where imaging, physiology, and clinical trajectory make it clear that the lungs are not going to recover. But determining that with confidence is harder than it sounds. ARDS injury tends to look different from region to region within the same lung, and even a tissue biopsy often cannot reliably tell you whether what you’re seeing is severe-but-recoverable injury or destruction that is truly permanent. The default clinical posture is to keep supporting the patient and hope for recovery, which, in cases where recovery is impossible, means delaying a decision that could have been made earlier.
Even when transplantation is identified as the right path, most of these patients cannot safely receive one. Three interconnected problems stand in the way:
- Active infection makes transplantation unsafe
Placing a newly transplanted organ into a patient with ongoing sepsis carries an extremely high risk of infecting the new lungs before they ever have a chance to function. In this case, the organism driving the infection was carbapenem-resistant, meaning the antimicrobial options available to control it were severely limited. As long as the infected lungs remained in the patient, there was no safe path to transplantation.
- Immunosuppression compounds the risk
Even if infection could be partially controlled, the immunosuppression required after transplantation to prevent rejection creates a second, compounding problem. A patient already losing the battle against a drug-resistant organism is in no position to have their immune defenses further suppressed. The two issues together (active infection and the immunosuppression transplantation requires) create a situation where the standard path to transplant is effectively closed.
Bilateral pneumonectomy theoretically solves both problems at once by removing the infectious source entirely. But it introduces a third problem that is equally serious.
- Removing both lungs creates a hemodynamic crisis
Most clinicians think of the lungs primarily as gas exchange organs, but they also serve a critical circulatory function: they act as a pressure buffer for the right side of the heart, absorbing the constant fluctuations in blood flow that occur with every heartbeat. If you remove both lungs, and that buffer is gone. The right ventricle is suddenly exposed to uncontrolled swings in pressure and volume that standard ECMO circuits are not designed to manage.
In a patient already in septic shock (where the cardiovascular system is already under extreme stress), this can rapidly cause right heart failure or disruption at the surgical staple line where the pulmonary artery was divided. Prior attempts at post-pneumonectomy mechanical support using conventional ECMO configurations ran into exactly this problem.
What Made This System Different
The Northwestern team designed what they describe as a total artificial lung (TAL) system specifically to address these physiologic constraints. Two elements were particularly important.
The first was a flow-adaptive shunt between the right pulmonary artery and the right atrium, placed percutaneously using a Protek-Duo cannula. This shunt created a low-resistance alternative pathway for right ventricular output that could respond dynamically to pressure differentials, effectively mimicking the capacitance function of the missing pulmonary vascular bed. Intraoperative testing confirmed the shunt was genuinely self-regulating, with flow through the conduit adjusting automatically from just over one liter per minute to more than six liters per minute depending on what the heart needed in real time.
The second key feature was the use of two independent return conduits delivering oxygenated blood directly into the left atrium. This kept the left ventricle continuously filled and the aortic valve opening normally with every beat, which is critical for preventing blood from pooling and clotting inside the heart. Having two independent conduits also meant that if any part of the circuit failed, flow could continue through the other without interruption. In a patient with no lungs, even a momentary loss of support is not survivable, so that redundancy was a deliberate and essential design choice.
Within hours of initiating this circuit following pneumonectomy, vasopressor requirements declined substantially and were discontinued approximately 12 hours later. Lactate, which had been markedly elevated prior to surgery, normalized within 24 hours. Biventricular function remained preserved throughout the bridge period, and the patient was stabilized to the point where transplantation became possible.
The Outcome
48 hours after pneumonectomy, the patient received a bilateral lung transplantation. He was extubated on postoperative day seven and discharged eight weeks later. At two years of follow-up, he demonstrates excellent cardiopulmonary function with full functional independence, a remarkable result for a patient who, under any conventional treatment framework, had no remaining options.
Is This Replicable?
The equipment at the center of this circuit, the Protek-Duo cannula, is commercially available and already in use at many advanced ECMO centers for right ventricular support. However, what was novel here was the circuit configuration and the clinical judgment to deploy it.
The surgical expertise and institutional infrastructure required place this at the more specialized end of the ECMO spectrum, but for centers already operating mature ECMO programs with experience in complex configurations and bridge-to-transplant support, this is not a distant frontier. Cases like this one are part of how the field advances: they establish that something is possible, document how it was done, and give other teams a concrete framework to build from.
What This Means for ECMO
This case sits at the far edge of what extracorporeal support currently makes possible. But the far edge has a way of becoming the middle over time. A therapy that was once confined to a handful of specialized centers is now offered at hospitals across the country, and the indications for ECMO continue to expand as evidence accumulates and expertise spreads.
Bridge-to-transplant support is one of the most active frontiers in that expansion. The COVID-19 pandemic forced a reckoning with the reality that some patients with acute lung failure are not going to recover, and it accelerated the field’s willingness to consider transplantation in that setting. This case pushes that frontier further, demonstrating that even patients who cannot safely receive a transplant by conventional criteria may have a viable pathway forward with the right support strategy.
For ECMO clinicians and program leaders, the practical takeaway is not that every center needs to prepare for bilateral pneumonectomy, but rather that the field is moving, and the cases being published today are shaping the standard of care tomorrow. Understanding the physiologic rationale behind the total artificial lung configuration is the kind of foundational knowledge that prepares teams to recognize, refer, and ultimately participate in the next generation of advances.
ECMO has always been a field that rewards keeping up. This case is a reminder of why that remains true.
